MedTrace Logo

Efficacy and Safety of Namilumab for Moderate-to-severe Axial Spondyloarthritis

NCT03622658 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2022-03-08

Study results available
· View outcomes & findings →

Summary

The study will assess the effect of namilumab, a GM-CSF inhibitor, on the clinical response in subjects with axial spondyloarthritis. Subjects will receive treatment with either namilumab or placebo.

Conditions

  • Axial Spondyloarthritis

Interventions

BIOLOGICAL

Placebo

Placebo solution for subcutaneous injection.

BIOLOGICAL

Namilumab

Namilumab solution for subcutaneous injection

Sponsors & Collaborators

  • Iqvia Pty Ltd

    collaborator INDUSTRY

  • Innovate UK

    collaborator OTHER_GOV

  • Izana Bioscience Ltd.

    lead INDUSTRY

Principal Investigators

  • Peter C Taylor, PhD · Botnar Research Centre, University of Oxford

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-06
Primary Completion
2020-02-04
Completion
2020-02-04

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03622658 on ClinicalTrials.gov